announced the US launch of LEQSELVI (deuruxolitinib) 8 mg tablets for treating adults with severe alopecia areata. The drug, available nationwide, showed rapid results in clinical trials, with 3% of patients achieving 80% scalp coverage in 8 weeks. LEQSELVI is an effective treatment option for severe alopecia areata, addressing a critical unmet need in the US. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

#StockInNews

662 likes